PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Practice Signal

Antipsychotics for ICU Delirium: A Decade of Negative Trials

This review helps pharmacists retire routine antipsychotics for ICU delirium, limit them to brief control of dangerous agitation, and build dexmedetomidine, melatonin, and the ABCDEF bundle into the delirium plan instead.

Bottom Line

Antipsychotics do not resolve ICU delirium, shorten hospitalization, or improve survival. Large randomized trials of haloperidol and ziprasidone (MIND-USA, AID-ICU) and of prophylactic haloperidol (REDUCE), two meta-analyses, and the 2025 PADIS guideline update converge on the same conclusion: haloperidol, ziprasidone, and atypical antipsychotics lack efficacy as delirium treatments in critically ill patients. Pharmacists should challenge reflexive antipsychotic orders for ICU delirium and instead champion the ABCDEF bundle, reserving antipsychotics only for brief management of severe agitation that threatens patient safety.

566
Patients in MIND-USA
1,000
Patients in AID-ICU
1,789
Patients in REDUCE
0
Trials Showing Benefit

State of Play

ICU delirium affects 30-80% of mechanically ventilated patients and is independently associated with prolonged hospitalization, cognitive impairment, and increased mortality. For decades, haloperidol was the reflexive pharmacologic response, anchored more by tradition and expert opinion than by rigorous evidence. Atypical antipsychotics such as quetiapine and ziprasidone followed haloperidol into common use on the assumption that dopamine D2 antagonism addressed an underlying neurochemical disturbance.

That assumption has not survived controlled testing. Between 2016 and 2025, randomized trials tested haloperidol, ziprasidone, quetiapine, olanzapine, and dexmedetomidine against placebo or each other for established ICU delirium. With the exception of the DahLIA study, which met its ventilator-free-hours primary endpoint, none of the other landmark trials met their primary efficacy endpoints. The MIND-USA trial (2018, N=566) found no reduction in delirium or coma duration with haloperidol or ziprasidone, and its long-term follow-up confirmed that null result persisted at 3 and 12 months across cognitive, functional, and quality-of-life domains. The AID-ICU trial (2022, N=1,000), the largest single RCT, found no significant effect on days alive outside the hospital at 90 days (adjusted mean difference 2.9 days, 95% CI −1.2 to 7.0). The REDUCE trial (2018, N=1,789) tested prophylactic haloperidol and found no survival benefit whatsoever.

What has emerged from this evidence is a clearer distinction between treating the symptom of agitation and treating the syndrome of delirium. The DahLIA trial (2016) showed that dexmedetomidine increased ventilator-free hours in agitated delirium patients ready for extubation, and the 4D trial (2025) confirmed dexmedetomidine controls agitation faster than placebo in non-intubated patients. DahLIA showed faster delirium resolution, whereas 4D did not; neither trial demonstrated an effect on longer-term delirium burden. Meanwhile, two meta-analyses (2024 and 2025) synthesized the cumulative RCT data and reached the same conclusion: antipsychotics provide no meaningful outcome benefit for ICU delirium.

🔒
Full Analysis: Subscribers Only
The complete evidence synthesis, practice recommendations, and open questions.
What Changed
How It Fits the Guidelines
Effect chart & evidence comparison
Evidence at a Glance
Practice Considerations
Open Questions
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this Practice Signal, every other Signal, and every deep analysis we publish, plus PDF reports.

Subscribe for $8/month →
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.
critical care|delirium|antipsychotics|haloperidol|dexmedetomidine|ICU|PADIS
🎓
Synthesized and reviewed by a licensed pharmacist
Each Practice Signal is built from our published deep analyses and checked for clinical accuracy before it goes live.
Not medical advice. PharmD Signal provides educational synthesis of published pharmacy and medical literature for practicing pharmacists. It is not a treatment recommendation for any individual patient; clinical decisions remain the responsibility of the treating clinician exercising independent professional judgment.
Thanks for the feedback!

← Back to Evidence Rounds